Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 2
Submit an article Journal homepage
1,857
Views
1
CrossRef citations to date
0
Altmetric
Articles

Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program

Stephen P. Mulligana Department of Haematology, Royal North Shore Hospital, Sydney, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1928-2098View further author information
ORCID Icon,
Stephen Opatb Monash Health, Monash University, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0002-0308-6458View further author information
ORCID Icon,
Chan Y. Cheahc Department of Haematology, Sir Charles Gairdner Hospital, Perth, Australia;d Department of Haematology, Pathwest Laboratory Medicine, Perth, Australia;e School of Medicine, University of Western Australia, Perth, AustraliaORCID Iconhttps://orcid.org/0000-0001-7988-1565View further author information
ORCID Icon,
Bryone Kussf Flinders Medical Centre and Finders University, Bedford Park, AustraliaView further author information
,
Mark Hertzbergg Department of Haematology, Prince of Wales Hospital, Sydney, AustraliaView further author information
,
Paula Marltonh Department of Haematology, Princess Alexandra Hospital, Brisbane, Australia;i University of Queensland School of Medicine, Brisbane, AustraliaView further author information
,
Sarah Poplarj Northland Cancer and Blood Services, Northland District Health Board, Whangarei, New ZealandView further author information
,
Andrea Puigk Real-world Evidence, Janssen-Cilag Pty Ltd, Sydney, AustraliaView further author information
,
Marija McGeachiel Medical and Scientific Affairs, Janssen-Cilag Pty Ltd, Sydney, AustraliaView further author information
,
Robert Weinkovem Te Rerenga Ora Blood & Cancer Centre, Wellington Hospital, Wellington, New Zealand;n Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New ZealandORCID Iconhttps://orcid.org/0000-0003-3645-7988View further author information
ORCID Icon &
Constantine S. Tamo Alfred Hospital and Monash University, Melbourne, AustraliaView further author information
 show all
Pages 312-318 | Received 24 Oct 2022, Accepted 12 Nov 2022, Published online: 24 Nov 2022

References

  • Therapeutic Goods Administration. Australian product information; IMBRUVICA® Ibrutinib capsules and tablets. Therapeutic Goods Administration; Canberra, ACT, Australia; 2021.
  • Brown JR, Hillmen P, O'Brien S, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia. 2018;32(1):83–91.
  • Barr PM, Robak T, Owen C, et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018;103(9):1502–1510.
  • Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770–778.
  • Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.
  • Barr PM, Owen C, Robak T, et al. Up to 8 years follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(11):3440–3450.
  • Dreyling M, Goy A, Hess G, et al. Long-term outcomes with ibrutinib treatment for patients with relapsed/refractory mantle cell lymphoma: a pooled analysis of 3 clinical trials with nearly 10 years of follow-up. Hemasphere. 2022;6(5):e712.
  • Medsafe. IMBRUVICA® ibrutinib New Zealand Data Sheet. Medsafe; Wellington, New Zealand; 2021.
  • von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies. Gac Sanit. 2008;22(2):144–150.
  • Weinkove R, Doocey R, Henderson R, et al. PB 1892 real world treatment persistence of New Zealand ibrutinib chronic lymphocytic leukaemia patients in a Named Patient Program. HemaSphere. 2019;3(S1):861–862.
  • Hertzberg M, Cheah CY, Tam C, et al. Real-world experience of Australian and New Zealand relapsed or refractory mantle cell lymphoma patients on ibrutinib in a Named Patient Program. Haematology Society of Australia and New Zealand Annual Scientific Meeting. Blood. 2018. P070
  • Blonde L, Khunti K, Harris SB, et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35(11):1763–1774.
  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood. 2016;127(20):2375–2390.
  • Mulligan SP, Opat S, Marlton P, et al. Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia. Br J Haematol. 2022;198(4):790–793.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.